A targeted immune therapy against artery disease using a liposome-linked ApoB fragment
Official title: Liposome-displayed ApoB fragment for active immunotherapy against atherosclerosis
Funded at Pop Biotechnologies, INC · NIH-11409692 · Data updated 2026-11-12
A first-in-class approach aims to train the immune system to fight atherosclerosis by using a tiny ApoB fragment displayed on a liposome to elicit a protective immune response.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pop Biotechnologies, INC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $309,794 |
| NIH project number | 1R41HL184798-01A1 |
| Project ID | NIH-11409692 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with ASCVD or high cardiovascular risk who could participate in future trial phases after establishing safety.
✕Less likely to help
People without ASCVD or with conditions that contraindicate immunotherapies may not benefit from this approach.
What this research studies
This project adapt a peptide from ApoB-100 attached to CoPoP liposomes to create a vaccine-like therapy for atherosclerosis. It builds on prior work showing that certain ApoB peptides can reduce plaque in mice, and partners with POP Biotechnologies to use their SNAP vaccine platform. The study will focus on formulating the peptide with CPQ adjuvants to drive strong cellular immune responses that may stabilize or reduce plaques. The research is designed to move from preclinical models toward potential human trials if safety and efficacy are demonstrated.
Why it matters
Potential benefit: If successful, this immune-based therapy could provide a novel way to reduce cardiovascular risk by targeting the immune component of ASCVD.
How similar studies have gone: Previous ApoB-focused immunotherapies showed atheroprotective effects in mouse models, but human data are not yet established.
Where this research is happening
-
Pop Biotechnologies, INC
Buffalo, United States Active
Researchers
- Principal investigator: Chyu, Kuang-Yuh — Pop Biotechnologies, INC
- Study coordinator: Chyu, Kuang-Yuh
Related research
Other NIH-funded projects on the same topics.
-
Targeting GITR to treat clogged arteries
Testing whether targeting a protein called GITR can calm artery inflammation and help people with atherosclerosis reduce dangerous plaque.
-
Exploring a new way to treat atherosclerosis using targeted immunotherapy.
This study is looking at how a protein called GITR affects the buildup of plaque in arteries, which can lead to heart problems, and aims to find new treatments that could help reduce inflammation and improve health for people with atherosclerosis.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.